Keum, HyeongseopAlbadawi, HassanZhang, ZefuGraf, ErinDos Santos, Pedro ReckGunduz, SeydaOklu, Rahmi2024-05-192024-05-1920240935-96481521-4095https://doi.org10.1002/adma.202309412https://hdl.handle.net/20.500.12713/4675Delivery of therapeutics to solid tumors with high bioavailability remains a challenge and is likely the main contributor to the ineffectiveness of immunotherapy and chemotherapy. Here, a catheter-directed ionic liquid embolic (ILE) is bioengineered to achieve durable vascular embolization, uniform tissue ablation, and drug delivery in non-survival and survival porcine models of embolization, outperforming the clinically used embolic agents. To simulate the clinical scenario, rabbit VX2 orthotopic liver tumors are treated showing successful trans-arterial delivery of Nivolumab and effective tumor ablation. Furthermore, similar results are also observed in human ex vivo tumor tissue as well as significant susceptibility of highly resistant patient-derived bacteria is seen to ILE, suggesting that ILE can prevent abscess formation in embolized tissue. ILE represents a new class of liquid embolic agents that can treat tumors, improve the delivery of therapeutics, prevent infectious complications, and potentially increase chemo- and immunotherapy response in solid tumors.eninfo:eu-repo/semantics/closedAccessAngiographyDeliveryEmbolizationImmunotherapyLarge Animal ModelsArticle38305472WOS:0011630957000012-s2.0-85185105333N/A10.1002/adma.202309412Q1